Effects of vilazodone on sexual functioning in healthy adults

Clayton, Anita H.; Durgam, Suresh; Li, Dayong; Chen, Changzheng; Chen, Laishun; Mathews, Maju; Gommoll, Carl; Szegedi, Armin

doi:10.1097/yic.0000000000000145

Cited by 17 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 2 indicates presumed mechanism of interference with sexual response with different classes of antidepressants as well as approximate risk of medication-associated dysfunction. 72–83…”

Section: Antidepressant Induced Sexual Dysfunctionmentioning

confidence: 99%

Women’s sexual dysfunction associated with psychiatric disorders and their treatment

Basson

Gilks

2018

Womens Health (Lond Engl)

143

106

View full text Add to dashboard Cite

Impairment of mental health is the most important risk factor for female sexual dysfunction. Women living with psychiatric illness, despite their frequent sexual difficulties, consider sexuality to be an important aspect of their quality of life. Antidepressant and antipsychotic medication, the neurobiology and symptoms of the illness, past trauma, difficulties in establishing relationships and stigmatization can all contribute to sexual dysfunction. Low sexual desire is strongly linked to depression. Lack of subjective arousal and pleasure are linked to trait anxiety: the sensations of physical sexual arousal may lead to fear rather than to pleasure. The most common type of sexual pain is 10 times more common in women with previous diagnoses of anxiety disorder. Clinicians often do not routinely inquire about their patients' sexual concerns, particularly in the context of psychotic illness but careful assessment, diagnosis and explanation of their situation is necessary and in keeping with patients' wishes. Evidence-based pharmacological and non-pharmacological interventions are available but poorly researched in the context of psychotic illness.

show abstract

Section: Antidepressant Induced Sexual Dysfunctionmentioning

confidence: 99%

Women’s sexual dysfunction associated with psychiatric disorders and their treatment

Basson

Gilks

2018

Womens Health (Lond Engl)

143

106

View full text Add to dashboard Cite

show abstract

“…Strikingly, the effect of gender was not investigated in relation to functional MRI (fMRI) measures in any trial. Further, two trials found no differences between men and women, but noted that the sample sizes were not large enough to conclude absence of gender differences in the observed effects (Clayton et al, 2017; Riedel et al, 2005). Thus, several effects of SSRI differed for the sexes but only five trials adjusted the statistical models for gender (Besnier et al, 2010; Knorr, Koefoed, Soendergaard, et al, 2016; J.…”

Section: Resultsmentioning

confidence: 93%

“…The newly retrieved trials and the trials from a previously published systematic review from our group in 2009 (Knorr & Kessing, 2010) resulted in a total of 51 trials (Abler, Grön, Hartmann, Metzger, & Walter, 2012; Abler et al, 2011; Allen, Lader, & Curran, 1988; Almeida et al, 2010; A. N. Simmons, Arce, Lovero, Stein, & Paulus, 2009; Arce, Simmons, Lovero, Stein, & Paulus, 2008; Besnier et al, 2010; Bilderbeck et al, 2014; Briscoe, Ertl, Tate, Dawling, & Davis, 2008; Browning et al, 2011; Bui et al, 2013; Carpenter et al, 2011; Chial et al, 2003; Clayton et al, 2017; Di Simplicio, Doallo, et al, 2014; Di Simplicio, Norbury, & Harmer, 2012; Di Simplicio, Norbury, Reinecke, & Harmer, 2014; Drueke et al, 2009, 2010; Fairweather, Pozzo, Kerr, Lafferty, & Hindmarch, 1997; Fisher et al, 2015; Gerdelat-Mas et al, 2005; Graf, Abler, Hartmann, Metzger, & Walter, 2013; Graf, Metzger, Walter, & Abler, 2016; Grillon, Chavis, Covington, & Pine, 2009; Haahr et al, 2014; Haastrup, Knorr, Erikstrup, Kessing, & Ullum, 2012; Harmer, Mackay, Reid, Cowen, & Goodwin, 2006; Harmer et al, 2004; Hergovich et al, 2000; Hinkelmann et al, 2010; J. G. Simmons & Allen, 2011; J.…”

Section: Resultsmentioning

confidence: 99%

“…(Haastrup et al, 2012; Knorr, Koefoed, Gluud, et al, 2016; Knorr, Koefoed, Soendergaard, et al, 2016; Knorr, Vinberg, Gade, et al, 2011; Knorr, Vinberg, Gether, et al, 2012; Knorr, Vinberg, Hansen, et al, 2011; Knorr, Vinberg, Mortensen, et al, 2012; Macoveanu, Knorr, et al, 2014). Regarding 5 trials, randomization by computer was described (Briscoe et al, 2008; Clayton et al, 2017; Harmer et al, 2006, 2004; Murphy et al, 2009; Talley et al, 2005). Harmer et al and Murphy et al, used the latter stratified randomization by age, gender, and IQ and Briscoe et all described a stratified block randomization done by an investigational pharmacy.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The effect of selective serotonin reuptake inhibitors in healthy subjects revisited: A systematic review of the literature.

Knorr¹,

Madsen²,

Kessing³

2019

Experimental and Clinical Psychopharmacology

View full text Add to dashboard Cite

Selective serotonin reuptake inhibitors (SSRIs) are the first-line drug in the treatment of depression, and the investigation of the biological effects of SSRIs in patients with depression and in healthy subjects may lead to a hypothesis regarding the yet largely unknown causes of depression. This systematic review points to effects of SSRIs increasing positive emotional processing and decreasing measures of divided and sustained attention which may be central features of depression.

show abstract

“… 49 Weight gain in the long-term MDD study was small (mean increase +1.7 kg), 49 in contrast to mean weight gains seen in long-term studies of other SSRI drugs (up to ~10 kg). 50 Additionally, vilazodone had no significant placebo-subtracted effect on sexual functioning in patients with MDD 51 or in healthy adult volunteers, 52 which is an important factor to consider when treating patients with sexual dysfunction associated with antidepressant treatment or with depressive disorder itself.…”

Section: Introductionmentioning

confidence: 99%

The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone

McIntyre¹

2017

NDT

View full text Add to dashboard Cite

Although many branded and generic antidepressants are approved for the treatment of major depressive disorder (MDD) in Canada, efficacy and tolerability differ among patients, and new treatment options are needed. Symptom types (eg, fatigue, energy/motivation, cognition, and functioning), medication type, treatment duration, and the need for maintenance therapy are factors that may influence treatment effectiveness. Three antidepressants, vortioxetine, levomilnacipran extended-release (ER), and vilazodone have recently become available in Canada. The aim of this review is to contextualize differences in their mechanistic and clinical profiles, thereby providing practitioners with knowledge to support treatment decisions. In trials versus placebo, each drug improved depressive symptoms in adult patients with MDD. The antidepressant effect of vortioxetine may be related to enhanced serotonergic activity via reuptake inhibition and agonism and/or antagonism of various serotonin receptors. Vortioxetine may also improve cognitive functioning in MDD, and has proven efficacious in relapse prevention. Nausea was the most commonly reported adverse event (AE); rates of sexual dysfunction were low and abrupt discontinuation was well tolerated. Levomilnacipran ER, a serotonin norepinephrine reuptake inhibitor, demonstrated greater improvement versus placebo in functional impairment as well as depressive symptoms; in post hoc analyses, improvement in symptoms of motivation and energy were observed. Nausea was the most commonly reported AE; gradual discontinuation is recommended to avoid discontinuation syndrome. Vilazodone is a serotonin reuptake inhibitor and partial serotonergic 5-HT1A receptor agonist. In addition to improvement in depressive symptoms, evidence suggests that vilazodone may be particularly well suited for depressed patients with high anxiety levels. Diarrhea, nausea, and headache were the most common AEs; low rates of sexual dysfunction were reported. The 2016 Canadian Network for Mood and Anxiety Treatments guidelines for MDD includes vortioxetine as a first-line treatment; levomilnacipran ER and vilazodone are considered as second-line treatments due to lack of relapse prevention data at the time of approval.

show abstract

Effects of vilazodone on sexual functioning in healthy adults

Abstract: Supplemental Digital Content is available in the text.

Cited by 17 publications

References 22 publications

Women’s sexual dysfunction associated with psychiatric disorders and their treatment

Women’s sexual dysfunction associated with psychiatric disorders and their treatment

The effect of selective serotonin reuptake inhibitors in healthy subjects revisited: A systematic review of the literature.

The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone

Contact Info

Product

Resources

About